Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ccm.2016.04.006 http://scihub22266oqcxt.onion/10.1016/j.ccm.2016.04.006 C5902187!5902187!27514590     free     free     free       Clin+Chest+Med 2016 ; 37 (3): 431-40 Nephropedia Template TP {{tp|p=27514590|t=2016. Pulmonary Alveolar Proteinosis Syndrome |pdf=|usr=}}{{27514590}} gab.com Text Pulmonary Alveolar Proteinosis Syndrome JO: Clin Chest Med http://www.kidney.de/pget.php?&tw=1&pmid=27514590 #FOAvip Pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by the accumulation of surfactant in alveoli and terminal airways resulting in respiratory failure. PAP comprises part of a spectrum of disorders of surfactant homeostasis (clearance and production). The surfactant clearance disorders are caused by disruption of GM-CSF signaling (primary PAP) or by an underlying disease that impairs alveolar macrophage functions including surfactant catabolism (secondary PAP). Primary PAP is related to alveolar macrophage dysfunction due to the disruption of GM-CSF signaling caused by a high serum level of anti-GM-CSF autoantibody (autoimmune PAP) (?90%) or by the mutations in the GM-CSF receptor genes (hereditary PAP). The surfactant production disorders are caused by mutations in genes required for normal surfactant production. The PAP syndrome can be identified based on history, radiologic and bronchoalveolar lavage and/or histopathological findings. The diagnosis of PAP-causing diseases in secondary PAP requires further studies. Whole lung lavage is the current standard therapy and promising new pharmacologic therapies are currently in development. Twit Text FOAVip Pulmonary Alveolar Proteinosis Syndrome ????Clin Chest Med http://www.kidney.de/pget.php?&tw=1&pmid=27514590 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27514590 #FOAvip English Wikipedia <ref>{{Cite pmid|27514590}}</ref> Pulmonary Alveolar Proteinosis Syndrome #MMPMID27514590 Suzuki T; Trapnell BC Clin Chest Med 2016[Sep]; 37 (3): 431-40 PMID27514590show ga Pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by the accumulation of surfactant in alveoli and terminal airways resulting in respiratory failure. PAP comprises part of a spectrum of disorders of surfactant homeostasis (clearance and production). The surfactant clearance disorders are caused by disruption of GM-CSF signaling (primary PAP) or by an underlying disease that impairs alveolar macrophage functions including surfactant catabolism (secondary PAP). Primary PAP is related to alveolar macrophage dysfunction due to the disruption of GM-CSF signaling caused by a high serum level of anti-GM-CSF autoantibody (autoimmune PAP) (?90%) or by the mutations in the GM-CSF receptor genes (hereditary PAP). The surfactant production disorders are caused by mutations in genes required for normal surfactant production. The PAP syndrome can be identified based on history, radiologic and bronchoalveolar lavage and/or histopathological findings. The diagnosis of PAP-causing diseases in secondary PAP requires further studies. Whole lung lavage is the current standard therapy and promising new pharmacologic therapies are currently in development. äPulmonary Alveolar Proteinosis Syndrome (epmc).pdf DeepDyve Pubget Overpricing